Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-547 in Super-Refractory Status Epilepticus
NCT02052739Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Mar 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brexanolone in status epilepticus (SE) (2 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Treatment-Emergent Adverse Events, National Institutes of Health Stroke Scale at Day 29 and 4 more. Started Mar 2014; status: completed.
02
Drugs
brexanolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT02052739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052739.